Ark Therapeutics Group plc.(AKT.L) announced that it has successfully completed the work requested by the US Food and Drug Administrationto qualify a potency test for Trinam. As a result, the FDA has now notified the Company that it can commence patient recruitment into its Trinam Phase III trial.
Trinam is Ark's novel gene-based medicine to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery.
The Phase III study is a US multi-centre, randomised, controlled trial, in which the efficacy and safety of Trinam will be investigated in patients with end-stage renal disease (ESRD) requiring vascular access for haemodialysis.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.